Breast cancer carcinomatous meningitis: Differences in survival depending on biological subtype, performance status, and treatment methods.

Niwińska, Anna; Rudnicka, H; Murawska, Magdalena

doi:10.1200/jco.2011.29.15_suppl.1073

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The number of BM is an important factor for prognosis as well as treatment, as surgery or radiosurgery is usually only applied in patients with oligometastatic (1–3 metastases) disease ( Kamar and Posner, 2010 ; Niwinska et al , 2011a , 2011b ). Recently, an influence of breast cancer subtypes on the number of BM at first diagnosis was postulated.…”

Section: Discussionmentioning

confidence: 99%

“…Carcinomatous meningitis, just like BM, occurs late during the course of the disease and treatment options are very limited ( de Azevedo et al , 2011 ). While breast cancer subtype influences overall survival after the diagnosis of carcinomatous meningitis, little is known about risk factors ( Lee et al , 2011 ; Niwinska et al , 2011a , 2011b ). In our study, patients with luminal subtype were at higher risk for the development of carcinomatous meningitis compared to patients with HER-2 or triple-negative disease (19.6% vs 3.2% vs 9.3% P =0.002).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Brain metastases free survival differs between breast cancer subtypes

et al. 2012

View full text Add to dashboard Cite

Background:Brain metastases (BM) are frequently diagnosed in patients with HER-2-positive metastatic breast cancer; in addition, an increasing incidence was reported for triple-negative tumours. We aimed to compare brain metastases free survival (BMFS) of breast cancer subtypes in patients treated between 1996 until 2010.Methods:Brain metastases free survival was measured as the interval from diagnosis of extracranial breast cancer metastases until diagnosis of BM. HER-2 status was analysed by immunohistochemistry and reanalysed by fluorescent in situ hybridisation if a score of 2+ was gained. Oestrogen-receptor (ER) and progesterone-receptor (PgR) status was analysed by immunohistochemistry. Brain metastases free survival curves were estimated with the Kaplan–Meier method and compared with the log-rank test.Results:Data of 213 patients (46 luminal/124 HER-2/43 triple-negative subtype) with BM from breast cancer were available for the analysis. Brain metastases free survival differed significantly between breast cancer subtypes. Median BMFS in triple-negative tumours was 14 months (95% CI: 11.34–16.66) compared with 18 months (95% CI: 14.46–21.54) in HER-2-positive tumours (P=0.001) and 34 months (95% CI: 23.71–44.29) in luminal tumours (P=0.001), respectively. In HER-2-positive patients, co-positivity for ER and HER-2 prolonged BMFS (26 vs 15 m; P=0.033); in luminal tumours, co-expression of ER and PgR was not significantly associated with BMFS. Brain metastases free survival in patients with lung metastases was significantly shorter (17 vs 21 months; P=0.014).Conclusion:Brain metastases free survival in triple-negative breast cancer, as well as in HER-2-positive/ER-negative, is significantly shorter compared with HER-2/ER co-positive or luminal tumours, mirroring the aggressiveness of these breast cancer subtypes.

show abstract

Section: Discussionmentioning

confidence: 99%